Menu Search
Equities

AddLife AB

1AD1:BER

AddLife AB

Actions
  • Price (EUR)8.62
  • Today's Change-0.205 / -2.32%
  • Shares traded450.00
  • 1 Year change-17.90%
  • Beta--
Data delayed at least 15 minutes, as of May 02 2024 20:43 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AddLife AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The Company operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The Company operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.

  • Revenue in SEK (TTM)9.80bn
  • Net income in SEK79.00m
  • Incorporated2014
  • Employees2.29k
  • Location
    AddLife ABBrunkebergstorg 5, Box 3145STOCKHOLM 103 62SwedenSWE
  • Phone+46 842003830
  • Websitehttps://www.add.life/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.